Valuation: ChitogenX Inc.

Market Cap 831K 598K 518K 488K 443K 57.12M 838K 5.83M 2.24M 29.08M 2.25M 2.2M 92.28M P/E 2023
-2.01x
P/E 2024 -3.99x
Enterprise Value 4.67M 3.36M 2.91M 2.74M 2.49M 321M 4.71M 32.77M 12.6M 163M 12.62M 12.34M 519M EV / Sales 2023
-
EV / Sales 2024 -
Free-Float
100%
Yield 2023 *
-
Yield 2024 -
3 years 0
Extreme 0.005
0.14
5 years 0
Extreme 0.005
0.6
10 years 0
Extreme 0.005
1
Manager TitleAgeSince
Chief Executive Officer 65 2024-02-27
Director of Finance/CFO 62 2018-09-17
Chief Tech/Sci/R&D Officer 68 -
Director TitleAgeSince
Chairman 67 2019-03-05
Chairman 65 2016-07-25
Chairman 65 -
Date Insider Type Main position Quantity % Market Cap. Importance
11/19/24 Buy

Chief Financial Officer

710,000 0.8541%
7/17/24 Option

Chief Executive Officer

544,400 0.6549%
7/17/24 Option

General Counsel

100,000 0.1203%
Change 5-day change 1-year change 3-year change Capi.($)
-.--%-.--%-.--%-95.00% 300K
+0.56%-5.82%-2.45%+9.99% 45.48B
+0.66%-2.34%+340.62%+524.38% 43.68B
+1.49%-0.78%+41.90%+22.65% 43.09B
+2.11%-1.24%+9.09%+76.85% 39.4B
+0.34%-4.94%+9.34%+40.23% 31.91B
+0.53%-2.08% - - 17.31B
+1.34%+0.70%+21.35%+111.39% 16.4B
+2.07%-0.77%+13.07%+32.89% 14.24B
-1.85%-5.33%+78.63%+34.13% 13.28B
Average +0.72%-7.68%+56.84%+84.17% 26.48B
Weighted average by Cap. +0.94%-3.26%+76.00%+126.85%

Financials

2023 2024
Net sales - -
Net income -6.23M -4.48M -3.88M -3.66M -3.32M -428M -6.28M -43.71M -16.81M -218M -16.83M -16.46M -692M -1.55M -1.12M -968K -912K -828K -107M -1.57M -10.9M -4.19M -54.37M -4.2M -4.11M -173M
Net Debt 6.21M 4.46M 3.87M 3.64M 3.31M 426M 6.25M 43.54M 16.75M 217M 16.77M 16.4M 689M 3.84M 2.76M 2.39M 2.25M 2.05M 264M 3.87M 26.94M 10.36M 134M 10.38M 10.15M 426M
Logo ChitogenX Inc.
ChitogenX Inc. is a Canada-based clinical-stage regenerative medicine company. The Company is engaged in the development of therapeutic tissue repair technologies to improve tissue healing. The Company is committed to the clinical development of its proprietary RESTORE technology platform, a muco-adhesive CHITOSAN based biopolymer matrix, specifically designed to deliver biologics such as platelet-rich plasma (PRP) or bone marrow aspirate concentrate (BMAC), to enhance healing in various musculoskeletal conditions. Ortho-R, its lead Chitosan-PRP hybrid biologic implant combination product, is formulated and designed to increase the healing rates of occupational and sports related injuries to tendons, ligaments, and cartilage such as the meniscus. Its other formulations are being developed to leverage the technology's performance characteristics, such as tissue adhesion, pliability, and ability to deliver biologics or therapeutics to various tissues damaged by trauma or disease.
Employees
-

Annual profits - Rate of surprise

  1. Stock Market
  2. Stocks
  3. CHGX Stock
40% Discount: Identify Tomorrow's Best Investments With The Best Subscriber-Only Tools!
d
:
:
SEIZE THE OFFER!